Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent<i>Mycobacterium tuberculosis</i>Infection
Andrey Borisov(Saratov State Medical University), Andrew Vernon(The University of Texas at El Paso), Carla A. Winston(National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention), Leeanna Allen(National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention), Gibril J. Njie(National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention), Rachel Yelk Woodruff(National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention), Deron C. Burton(National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention), Sapna Bamrah Morris, Philip LoBue(Centers for Disease Control and Prevention), Stefan Goldberg
Cited by 110
Related Papers
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
|Clinical Infectious Diseases|2016|1.5k
Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.
|PubMed|2010|1.1k
Guidelines for Using the QuantiFERON-TB Gold Test for Detecting Mycobacterium tuberculosis Infection, United States
|PsycEXTRA Dataset|2005|694
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
|New England Journal of Medicine|2021|548